MAPT and Cognitive impairment: Because we have previously shown that reducing total tau levels by just 15–20% mitigates tau pathology and cognitive impairment in the PS19 mouse model11,12, we wanted to see whether partially reducing Tyk2 function in vivo (~50% reduction) could be a viable therapeutic strategy for decreasing tau levels and mitigating tau pathology.